Century Therapeutics, Inc. (IPSC) Tops Q1 EPS by 96c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q1 EPS of $0.89, $0.96 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $109.16 million versus the consensus estimate of $19.94 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• SpaceX short interest at 5-7% of float - S3 Partners